The FDA's HRT Warning Removal: What It Means for UK Women

For more than two decades, hormone replacement therapy (HRT) carried the FDA's most severe warning label in the United States: the black box warning. This label, reserved for drugs with the most serious safety concerns, shaped medical practice worldwide, frightened patients, and kept millions of women from accessing treatment for debilitating menopausal symptoms.

In 2025, the FDA removed this warning. While this is a US regulatory decision, its impact is global. The original warning influenced prescribing habits in the UK and across the NHS, and the removal signals a fundamental re-evaluation of the evidence. Understanding what changed, and what it means for UK women, matters.

A brief history: how fear shaped HRT prescribing

To understand the significance of the removal, you need to understand how the fear developed in the first place.

Before 2002: the era of confidence

Through the 1990s, hormone therapy was widely prescribed. Millions of women used it not just for symptom relief but for perceived cardiovascular protection and disease prevention. HRT was considered safe and beneficial.

2002: the WHI bombshell

The Women's Health Initiative (WHI) was a large randomised controlled trial designed to provide definitive evidence about hormone therapy. In July 2002, researchers stopped one arm of the trial (oestrogen plus progestin in women with a uterus) early because of safety concerns. The headlines were alarming: increased risks of breast cancer, heart disease, stroke, and blood clots.

The reaction was swift and dramatic. HRT prescriptions dropped by 50% or more across the US, UK, and Europe. The FDA added the black box warning. GPs in the UK stopped prescribing hormone therapy. Women who were taking it stopped abruptly, often without medical guidance. An entire generation of clinicians was trained to view hormone therapy with suspicion.

2002-2020: the slow correction

In the years following the WHI publication, the data was reanalysed extensively. Several critical nuances emerged that had been lost in the initial headlines:

• Age matters enormously. The average age of participants in the WHI was 63. Most women were more than a decade past menopause when they started hormone therapy. Subsequent analyses showed that the risks identified in the WHI were concentrated in older women who started HRT late, while younger women (those within 10 years of menopause onset) showed a very different risk profile.
• The "timing hypothesis." Research increasingly supported what became known as the timing hypothesis: hormone therapy started near the onset of menopause appears to be protective for cardiovascular health, while therapy started many years later may increase risk. This distinction was absent from the original WHI reporting.
• Type of hormone matters. The WHI used oral conjugated equine oestrogens and medroxyprogesterone acetate (a synthetic progestin). Subsequent research suggested that transdermal oestrogen (patches) carries lower risks for blood clots and stroke, and that micronised progesterone may have a more favourable safety profile than synthetic progestins.
• Oestrogen-only therapy was different. The WHI's oestrogen-only arm (for women without a uterus) actually showed a reduced risk of breast cancer and no increase in cardiovascular events. This result was often overlooked in the general alarm.
• Absolute risk vs. relative risk. The WHI risks, when expressed in absolute terms, were small. For example, the increased breast cancer risk amounted to approximately 1 additional case per 1,000 women per year. The headlines reported relative risk increases, which sounded much more alarming.

What the FDA's removal means for the UK

While the MHRA (the UK's medicines regulator) operates independently, FDA decisions carry significant influence globally. The removal of the black box warning reinforces what UK bodies have already been moving toward.

NICE updated its menopause guidance in 2015 (and subsequent reviews) to recommend HRT as a first-line treatment for vasomotor symptoms, and the British Menopause Society has consistently advocated for evidence-based prescribing. The FDA's decision aligns international regulatory sentiment.

What the removal signals

• Hormone therapy, when used appropriately, has an acceptable safety profile for the intended population
• May further reduce the stigma and fear that have kept women and GPs from considering HRT
• Aligns with the positions of NICE, the British Menopause Society, and the International Menopause Society
• May encourage improved menopause training in UK medical schools, where education has been inconsistent

What the removal does not do

• It does not mean hormone therapy is appropriate for everyone
• It does not eliminate all risks associated with HRT
• It does not change the recommendation for individualised decision-making
• It does not mean women should start HRT without consulting their GP or menopause specialist

The human cost of the fear era

The two decades of heightened fear around HRT had real consequences in the UK:

• Untreated symptoms. Surveys have consistently shown that the majority of symptomatic menopausal women in the UK were not receiving treatment. Many women suffered from severe hot flushes, sleep disruption, vaginal atrophy, and mood changes without relief because they or their GPs were afraid of hormone therapy.
• Increased fractures. As HRT use declined, osteoporotic fractures increased in older women who might have benefited from hormone therapy's bone-protective effects.
• GP knowledge gaps. Medical education on menopause in the UK has been inadequate. The British Menopause Society has highlighted that many UK medical schools provide minimal menopause training, leaving GPs uncomfortable with prescribing HRT.
• Rise of unregulated alternatives. As women sought relief outside of conventional HRT, the market for unregulated "bioidentical" hormone products, supplements, and unproven remedies expanded substantially.

What the current evidence says about HRT

The scientific consensus, as reflected by NICE, the British Menopause Society, and international bodies, can be summarised as follows:

For whom is HRT most appropriate?

• Women with moderate to severe vasomotor symptoms (hot flushes, night sweats)
• Women under 60 or within 10 years of menopause onset
• Women with early menopause (before age 45), where HRT is recommended at least until the average age of natural menopause
• Women with genitourinary syndrome of menopause (vaginal dryness, painful intercourse)
• Women at elevated risk of osteoporosis who cannot take other bone-protective medications

Benefits supported by evidence

• Effective relief of hot flushes and night sweats (the primary indication)
• Improvement in sleep quality when disrupted by vasomotor symptoms
• Prevention of bone loss and reduction in fracture risk
• Treatment of vaginal dryness and genitourinary symptoms
• Potential cardiovascular benefit when initiated near menopause onset (timing hypothesis)
• Improvement in mood and quality of life

Risks that remain

• Breast cancer: Combined oestrogen-progestogen therapy may modestly increase breast cancer risk after 3-5 years of use. Oestrogen-only therapy does not appear to increase risk and may reduce it.
• Blood clots: Oral oestrogen increases the risk of venous thromboembolism. Transdermal oestrogen (patches) does not appear to carry this risk.
• Stroke: Oral oestrogen may slightly increase stroke risk, particularly in women over 60. Again, transdermal delivery appears to mitigate this.
• Endometrial cancer: Unopposed oestrogen in women with a uterus increases endometrial cancer risk. This is why progestogen is always added for women who have not had a hysterectomy.

What this means for you personally

If you are currently taking hormone therapy, this news is reassuring but does not change your management plan. Continue working with your GP or menopause specialist to ensure your current regimen is appropriate for your individual situation.

If you have been avoiding hormone therapy due to fear, this is a good time to revisit that decision with your GP. The conversation should include:

1. Your symptoms. How severe are they? How much do they affect your quality of life?
2. Your age and time since menopause. The benefit-risk ratio is most favourable for women under 60 or within 10 years of menopause onset.
3. Your individual risk factors. Personal and family history of breast cancer, blood clots, stroke, and cardiovascular disease all factor into the decision.
4. Type and route of administration. Transdermal oestrogen and micronised progesterone (such as Utrogestan, available on NHS prescription) generally have the most favourable safety profile.
5. Duration. There is no arbitrary time limit on HRT. The decision to continue should be reviewed periodically based on ongoing symptoms and risk assessment.

The broader significance

The removal of the HRT black box warning is more than a regulatory update. It represents a correction of a two-decade-long overcorrection. The initial WHI findings were important, but their misinterpretation and overapplication caused significant harm: women suffered unnecessarily, clinical practice shifted away from evidence-based treatment, and a generation of clinicians was undertrained in menopause management.

For women navigating menopause in the UK today, the message is cautiously encouraging: hormone therapy, when used appropriately by the right patients at the right time, is a safe and effective treatment option. NICE guidance supports this, the British Menopause Society supports this, and now the FDA's labelling reflects it too.

The bottom line

The removal of the black box warning from HRT marks a significant shift in how hormone therapy is officially regarded worldwide. It does not make HRT risk-free, and it does not make it appropriate for everyone. What it does is move the conversation from fear to informed decision-making.

If menopausal symptoms are affecting your quality of life, you deserve a thorough, evidence-based conversation with your GP or menopause specialist about all your options, including hormone therapy. The era of reflexive avoidance of HRT is over. The era of individualised, informed treatment has arrived.